AstraZeneca Annual Report and Form 20-F Information 2016足球外围app


体育外围app软件


体育外围app软件

2017 should be a turning point in our journey as we bring new medicines to patients across the globe.

Pascal Soriot, Chief Executive Officer

体育外围app软件

Total Revenue*
体育外围app软件

足球外围app


* As detailed on page 142 of the downloadable PDF of the Annual Report, Total Revenue consists of Product Sales and Externalisation Revenue.

Net cash flow from operating activities
体育外围app软件

足球外围app




体育外围app软件

体育外围app软件

A global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.


体育外围app软件

Our strategic priorities reflect how we are working to achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.





体育外围app软件

体育外围app软件

Distinctive R&D capabilities: small molecule and biologic medicine, including immunotherapies and protein engineering, as well as devices, biomarkers and translational science.



体育外围app软件



体育外围app软件




体育外围app软件


Commercial Highlights:
体育外围app软件

  • Emerging Markets: Stable (growth of 6% at CER), supported by China, up 4% (10% at CER) to $2,636 million
  • Diabetes: Growth of 9% (11% at CER), as Farxiga/Forxiga became our largest-selling Diabetes medicine
  • Japan: Sales up 8% (decline of 3% at CER), reflecting exchange rate impact and a biennial price reduction
  • Brilinta/Brilique sales grew by 36% (39% at CER)
  • Respiratory: A decline of 5% (3% at CER), reflecting US pricing pressure for Symbicort
  • New Oncology: Strong sales with Tagrisso delivering sales of $423 million in its first full year

体育外围app软件



体育外围app软件

1) California, US  2) Gaithersburg, MD, US 3) Boston, MA, US  4) Gothenburg, Sweden
5) Shanghai, China  6) Osaka, Japan


足球外围app

足球外围app

足球外围app

足球外围app


Cambridge, UK (HQ)


Gothenburg, Sweden


Gaithersburg, Maryland US



体育外围app软件

体育外围app软件

Our capital-allocation priorities strike a balance between the interests of the business, our financial creditors and shareholders, and support our progressive dividend policy.



Distributions to shareholders $m 2016 2015 2014
Dividends
3,561
3,486
3,521
Proceeds from issue of shares
(47) (43) (279)
Total 3,514 3,443 3,242

Dividend per Ordinary Share $          2016 2015 2014
Dividend per Ordinary Share
2.80 2.80 2.80

Dividend per Ordinary Share for 2016    $
Pence
SEK
Payment Date
First interim dividend 0.90
68.7
7.81
12 September 2016
Second interim dividend 1.90
150.2
16.57
20 March 2017
Total 2.80
218.9
24.38
 

AstraZeneca’s Directors take very seriously their responsibility to have a robust governance structure in place.

Leif Johansson, Chairman